Abstract
Background Long noncoding RNA (lncRNA) NR2F1-AS1 has been previously reported to be dysregulated in human cancers and implicated in the tumorigenesis and development of tumors. In this research, we detected the expression level and biological function of NR2F1-AS1 in breast cancer (BC). Methods The expression of NR2F1-AS1 in BC tissues and cell lines was determined by qRT-PCR analysis. The associations of NR2F1-AS1 expression with clinical characteristics and survival rate of BC patients were also analyzed. Cell proliferation, migration, and invasion were measured by the CCK-8 and Transwell assay. Results The results revealed that the total survival time of BC patients with high NR2F1-AS1 expression was lower than that of BC patients with low NR2F1-AS1 expression. Moreover, functional experiments demonstrated that knockdown of NR2F1-AS1 inhibited BC cell viability, migration, and invasion abilities, whereas overexpression of NR2F1-AS1 had the opposite effect. Mechanistic investigation revealed that NR2F1-AS1 can competitively bind with microRNA-641 (miR-641) in BC. These results revealed that NR2F1-AS1 functioned as an oncogene by sponging miR-641 expression in BC cell progression. Moreover, miR-641 was negatively correlated with NR2F1-AS1 in BC tissues. Conclusion Hence, NR2F1-AS1 was found to act as an oncogene in breast cancer by suppressing miR-641. We suggested that NR2F1-AS1 could be a potential biomarker for BC diagnosis and therapy.
Highlights
Breast cancer (BC) is reported to rank second in cancer incidence and fifth in cancer mortality [1]
RT-qPCR results displayed that NR2F1-AS1 was highly expressed in breast cancer (BC) tissues than in normal tissues (Figure 1(a))
NR2F1-AS1 was upregulated in BC cell lines (MCF-7, MDA-MB-231, BT-474, MDA-MB-468, BT-549, and HCC1937) compared with MCF-10A cells (Figure 1(b))
Summary
Breast cancer (BC) is reported to rank second in cancer incidence and fifth in cancer mortality [1]. LINC00963 was demonstrated to be upregulated in BC tissues, and overexpression of LINC00963 promoted cell proliferation, tumorigenesis, and radioresistance through antagonization of miR-324-3p and regulation of ACK1 [8]. NR2F1 antisense RNA 1 (NR2F1-AS1) has been reported to be pivotal in the Journal of Healthcare Engineering tumorigenesis and development of human cancers. Huang et al revealed that NR2F1-AS1 silencing suppressed cell migration, invasion, and oxaliplatin resistance by regulating the miR-363/ABCC1 axis in hepatocellular carcinoma [12]. Long noncoding RNA (lncRNA) NR2F1-AS1 has been previously reported to be dysregulated in human cancers and implicated in the tumorigenesis and development of tumors. We detected the expression level and biological function of NR2F1-AS1 in breast cancer (BC). Ese results revealed that NR2F1-AS1 functioned as an oncogene by sponging miR-641 expression in BC cell progression. We suggested that NR2F1-AS1 could be a potential biomarker for BC diagnosis and therapy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
